|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
gptkb:Cephalon
gptkb:Actavis_Generics
gptkb:Barr_Pharmaceuticals
|
|
gptkbp:CEO
|
gptkb:Richard_Francis
|
|
gptkbp:country
|
gptkb:Israel
|
|
gptkbp:division
|
gptkb:OTC
Generic Medicines
Specialty Medicines
|
|
gptkbp:founded
|
1901
|
|
gptkbp:foundedIn
|
gptkb:Jerusalem,_Ottoman_Empire
|
|
gptkbp:founder
|
gptkb:Chaim_Salomon
gptkb:Moshe_Levin
gptkb:Yitschak_Elstein
|
|
gptkbp:fullName
|
gptkb:Teva_Pharmaceutical_Industries_Ltd.
|
|
gptkbp:headquartersLocation
|
gptkb:Petah_Tikva,_Israel
|
|
gptkbp:industry
|
Pharmaceuticals
|
|
gptkbp:ISIN
|
IL0006290147
|
|
gptkbp:keyPerson
|
gptkb:David_Stark
gptkb:Eric_Hughes
gptkb:Eli_Kalif
gptkb:Eric_Drapé
gptkb:Richard_Daniell
gptkb:Sven_Dethlefs
gptkb:Vivek_Joshi
gptkb:Amir_Elstein
gptkb:Richard_Francis
|
|
gptkbp:listedOn
|
gptkb:New_York_Stock_Exchange
gptkb:Tel_Aviv_Stock_Exchange
|
|
gptkbp:logo
|
Teva Pharmaceutical Industries logo.svg
|
|
gptkbp:market
|
Global
|
|
gptkbp:netIncome
|
$-2.35 billion (2022)
|
|
gptkbp:notableProduct
|
gptkb:Ajovy
gptkb:Austedo
gptkb:Copaxone
|
|
gptkbp:numberOfEmployees
|
~37,000
|
|
gptkbp:parentCompany
|
None
|
|
gptkbp:products
|
Over-the-counter drugs
Generic drugs
Specialty medicines
|
|
gptkbp:rank
|
One of the largest generic drug manufacturers in the world
|
|
gptkbp:revenue
|
$15.8 billion (2022)
|
|
gptkbp:servesArea
|
Worldwide
|
|
gptkbp:stockExchange
|
gptkb:TASE
gptkb:NYSE
|
|
gptkbp:stockSymbol
|
gptkb:TEVA
|
|
gptkbp:subsidiary
|
gptkb:Teva_Active_Pharmaceutical_Ingredients
gptkb:Teva_Neuroscience
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:website
|
https://www.tevapharm.com/
|
|
gptkbp:bfsParent
|
gptkb:Teva_Pharmaceutical_Industries
|
|
gptkbp:bfsLayer
|
5
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
TEVA
|